The distribution of NYHA class III–IV (38.7% vs. 24.1%) and baseline CRP paralleled the gradation of NIIS, whereas eGFR and β-blocker use did not differ materially between groups.‘Incident cancer’ refers to the hospital-defined endpoint of tumour detection at re-admission or during a scheduled follow-up encounter. The gene discussed is CRP; the disease is cancer.